Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
Pfizer Inc has decided to price its COVID-19 vaccine candidate, BNT162b2 COVID-19, on the basis of the GDP of the country. The Chief Executive Officer of the American pharmaceutical company, Albert Bourla, has said the company will have tiered pricing to its middle-income nations, including India.
The COVID-19 vaccine developed by Pfizer and BioNTech was initially approved by Britain on December 2. A week after the approval, the initial shot was administered on December 8 to Margaret Keenan, a 90-year-old girl from Northern Ireland. An early riser, Keenan received the jab in her local hospital in Coventry, central England, a week before she turns 91.
Pfizer has applied for emergency use authorisation of its coronavirus vaccine in India. The firm is the first to do so in a country with the world’s second-highest variety of infections.
The US company approached Indian authorities on December 5, VK Paul, who’s advising the government on COVID-19 matters reportedly said.
India’s drugs regulator normally takes up to 90 days to decide on such applications but a decision on Pfizer’s vaccine could come much faster than that, Paul said.
The Pfizer shot needs to be kept at minus 70 degrees Celsius (-94 F) or below, temperatures that industry experts say many cold storage facilities in India will find it tough to keep.
India has reported more than 97.35 lakh COVID-19 instances, the planet’s second-highest following the United States, with more than 1.41 lakh deaths, according to the union health ministry’s data released on December 9.
